2-acetamido-N-propan-2-ylacetamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-acetamido-N-propan-2-ylacetamide
• 化学式: C₇H₁₄N₂O₂
• mdl: MFCD00711393
• 分子量: 158.2
• InChiKey: GGDSGMNBYKZAQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• FUNCTIONALIZED PYRROLIDINES AND USE THEREOF AS IAP INHIBITORS
  申请人：Laurent Alain

  公开号：US20120009141A1

  公开（公告）日：2012-01-12

  A compound of Formula 1: or a salt thereof, and methods for the use thereof, especially as an IAP inhibitor, as well as related compounds, compositions, and methods.

  一种化合物的化学式1，或其盐，以及其使用方法，特别是作为IAP抑制剂的方法，以及相关的化合物、组合物和方法。
• COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2
  申请人：Ghosh Shomir

  公开号：US20120214807A1

  公开（公告）日：2012-08-23

  The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R 1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions.

  本发明提供了一般式I的化合物：或其药学上可接受的盐，其中X，n，Y和R1在此总体上和子集中被定义。本发明的化合物是CCR2的抑制剂，因此可用于治疗各种炎症、过敏和自身免疫性疾病、障碍或病况。
• Compounds Useful as Antagonists of CCR2
  申请人：Ghosh Shomir

  公开号：US20090197884A1

  公开（公告）日：2009-08-06

  The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and autoimmune diseases, disorders, or conditions.

  本发明提供一般式I的化合物或其药学上可接受的盐，其中X、n、Y和R1在此概括和子集中定义。本发明的化合物是CCR2的抑制剂，因此可用于治疗各种炎症、过敏和自身免疫性疾病、紊乱或状况。
• Benzothiazole derivatives as DYRK1 inhibitors
  申请人：PHARMASUM THERAPEUTICS AS

  公开号：US10927106B2

  公开（公告）日：2021-02-23

  The present invention relates to compounds of Formula (I), which are DYRK1A and/or DYRK1B inhibitors, and their use in the treatment of neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), metabolic disorders such as Metabolic Syndrome or diabetes mellitus, and cancer.

  本发明涉及作为 DYRK1A 和/或 DYRK1B 抑制剂的式 (I) 化合物及其在治疗神经退行性疾病（如阿尔茨海默病 (AD) 和帕金森病 (PD)）、代谢性疾病（如代谢综合征或糖尿病）和癌症中的用途。
• IAP bir domain binding compounds
  申请人：Boudreault Alain

  公开号：US20080069812A1

  公开（公告）日：2008-03-20

  Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R 1 , R 2 , R 3 , R 100 , R 200 , R 300 , A, A 1 , BG, Q and Q 1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.